50 results
6-K
EX-99.3
MDNAF
Medicenna Therapeutics Corp.
30 Apr 24
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
3:07pm
and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
14 Feb 24
Interim condensed consolidated financial statements of
7:30am
compensation (non-cash)
Research and development tax credits
Other research and development expenses
Subsequent event
Effective February 5, 2024, the Company
6-K
EX-99.2
MDNAF
Medicenna Therapeutics Corp.
14 Feb 24
Interim condensed consolidated financial statements of
7:30am
;
the Company’s treatment as a passive foreign investment company and potential adverse U.S. federal income tax consequences associated with such treatment … -clinical
Clinical
Salaries and benefits
Licensing, patent legal fees and royalties
Stock based compensation
Research and development tax credits
Other
6-K
EX-99.1
MDNAF
Medicenna Therapeutics Corp.
14 Nov 23
Interim condensed consolidated financial statements of
12:00am
(non-cash)
Research and development tax credits
Other research and development expenses
Subsequent events
On November 2, 2023, the Company’s common
6-K
EX-99.2
MDNAF
Medicenna Therapeutics Corp.
14 Nov 23
Interim condensed consolidated financial statements of
12:00am
income tax consequences associated with such treatment;
the difficulty U.S. investors may face in bringing actions against the Company … tax credits
Other research and development expenses
R&D expenses of $3.1 million and $5.9 million were incurred during the three and six months ended
6-K
EX-99.2
ypwn0f
28 Jul 23
Interim condensed consolidated financial statements of
8:31am
6-K
EX-99.2
98pgw jjxik9
4 Nov 22
Interim condensed consolidated financial statements of
8:00am
6-K
EX-99.1
kxzsvu qlv
4 Nov 22
Interim condensed consolidated financial statements of
8:00am
6-K
EX-99.1
j2m02q4
15 Aug 22
Interim Condensed Consolidated Statements of Financial Position
8:00am
6-K
EX-99.2
ktv2ylkiq06f4qcwm1o
15 Aug 22
Interim Condensed Consolidated Statements of Financial Position
8:00am
6-K
EX-99.1
fhiovv6p7gavx47s0gx
11 Aug 22
Current report (foreign)
12:53pm
SUPPL
lbzryw17lu q1
10 Aug 22
Supplemental materials (foreign)
3:10pm
SUPPL
4r1 qih68f
8 Aug 22
Supplemental materials (foreign)
8:40pm
20-F
EX-1.3
i32b xf2gwudkly
22 Jun 22
Annual report (foreign)
5:04pm
20-F
EX-4.7
jdq2e6jd97b3zxxluq
22 Jun 22
Annual report (foreign)
5:04pm
20-F
EX-2.2
t2jec6 68a
22 Jun 22
Annual report (foreign)
5:04pm
20-F
EX-4.1
j3dy0f jtab39sfhrdb
22 Jun 22
Annual report (foreign)
5:04pm
20-F
r5tmv3jzi nntzp2
22 Jun 22
Annual report (foreign)
5:04pm